The introduction of cenegermin has increased awareness of neurotrophic keratopathy (NK), leading to earlier diagnosis and a shift toward less severe disease stages at presentation, according to a poster presented at the 2025 World Cornea Congress.
Researchers compared patient records from 2011 to 2022, dividing them into groups based on those seen before cenegermin was commercially available in 2019 (group 1) and from 2019 onward (group 2).
The study identified 241 patients, with annual cases rising from 12.7 in group 1 to 34.0 in group 2. The proportion of patients presenting with stage 1 NK increased from 42.2% to 64.7%, while more severe stage 3 cases declined from 10.8% to 2.9%. In addition, group 2 demonstrated better visual acuity and corneal sensitivity at presentation.
Reference
Olcucu O, et al. Balbuena-Pareja A, et al. Trends and Insights of a Tertiary Referral Hospital for Patients with Neurotrophic Keratopathy. Poster presented at: 2025 World Cornea Congress; March 20-22, 2025; Washington, DC.
Related Content
